India: Lupin Limited has announced the receipt of the Establishment Inspection Report (EIR) after closure of the U.S. FDA inspection of its Nagpur, India facility.
The inspection was carried out by the U.S. FDA for the facility between January 6, 2020 and January 10, 2020.
“We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid dosage facility. We remain committed to enhancing compliance and quality standards across all our manufacturing sites.” EIR, Nilesh Gupta, Managing Director, Lupin said, commenting on receipt.
